Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9P0J1
UPID:
PDP1_HUMAN
Alternative names:
Protein phosphatase 2C; Pyruvate dehydrogenase phosphatase catalytic subunit 1
Alternative UPACC:
Q9P0J1; B3KX71; J3KPU0; Q5U5K1
Background:
[Pyruvate dehydrogenase [acetyl-transferring]]-phosphatase 1, mitochondrial, also known as Protein phosphatase 2C and Pyruvate dehydrogenase phosphatase catalytic subunit 1, plays a pivotal role in cellular energy metabolism. It catalyzes the dephosphorylation and reactivation of the alpha subunit of the E1 component of the pyruvate dehydrogenase complex, a key step in the conversion of pyruvate to acetyl-CoA.
Therapeutic significance:
The protein is directly linked to Pyruvate dehydrogenase phosphatase deficiency, a condition characterized by lactic acidosis and neurological dysfunction. This association underscores the protein's potential as a target for therapeutic intervention in metabolic disorders.